Findings

What do systematic reviews say?

4,776 questions · 7,311 findings · 959 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1,498 · 20.5%GRADE not reported 303 · 4.1%Very low 1,839 · 25.2%Low 1,991 · 27.2%Moderate 1,277 · 17.5%High 403 · 5.5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Ultra‐low‐molecular‐weight heparin vs placebo

Clinically relevant bleeding · ambulatory cancer patients receiving chemotherapy

Ultra‐low‐molecular‐weight heparin showed no clear difference in clinically relevant bleeding compared with placebo (moderate certainty).

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 1.4 [0.9, 2.19]
1 study · 3172 participants
Moderate

Low molecular weight heparin vs no LMWH

Outcomes ( · people with cancer with thrombosis prophylaxis and central venous catheters

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low molecular weight heparin vs vitamin K antagonist (VKA)

Outcomes ( · people with cancer with thrombosis prophylaxis and central venous catheters

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low molecular weight heparin vs vitamin K antagonist (VKA)

All‐cause mortality (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters

Low‐molecular‐weight heparin (LMWH) showed no clear difference in all‐cause mortality (up to 3 months) compared with vitamin K antagonist (VKA) (low certainty).

1 finding from 1 review

Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes only
RR 0.94 [0.56, 1.59]
3 studies · 561 participants
Low

Low molecular weight heparin vs vitamin K antagonist (VKA)

Symptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters

It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes symptomatic catheter‐related thrombosis (up to 3 months) compared with vitamin K antagonist (VKA) (very low certainty).

1 finding from 1 review

Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes only
RR 1.83 [0.44, 7.61]
2 studies · 327 participants
Very low

Low molecular weight heparin vs no LMWH

All‐cause mortality (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters

Low‐molecular‐weight heparin (LMWH) showed no clear difference in all‐cause mortality (up to 3 months) compared with no LMWH (low certainty).

1 finding from 1 review

Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes only
RR 0.82 [0.53, 1.26]
5 studies · 1236 participants
Low

Low molecular weight heparin vs vitamin K antagonist (VKA)

Symptomatic catheter‐related thrombosis measured as asymptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters

It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes symptomatic catheter‐related thrombosis measured as asymptomatic… compared with vitamin K antagonist (VKA) (very low certainty).

1 finding from 1 review

Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes only
RR 1.61 [0.75, 3.46]
2 studies · 317 participants
Very low

Low molecular weight heparin vs vitamin K antagonist (VKA)

Pulmonary embolism · people with cancer with thrombosis prophylaxis and central venous catheters

Low‐molecular‐weight heparin (LMWH) showed no clear difference in pulmonary embolism (up to 3 months) compared with vitamin K antagonist (VKA) (low certainty).

1 finding from 1 review

Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes only
RR 1.7 [0.74, 3.92]
2 studies · 327 participants
Low

Low molecular weight heparin vs vitamin K antagonist (VKA)

Major bleeding · people with cancer with thrombosis prophylaxis and central venous catheters

It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes major bleeding (up to 3 months) compared with vitamin K antagonist (VKA) (very low certainty).

1 finding from 1 review

Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes only
RR 3.11 [0.13, 73.11]
2 studies · 289 participants
Very low

Low molecular weight heparin vs vitamin K antagonist (VKA)

Minor bleeding · people with cancer with thrombosis prophylaxis and central venous catheters

It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes minor bleeding (up to 3 months) compared with vitamin K antagonist (VKA) (very low certainty).

1 finding from 1 review

Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes only
RR 0.95 [0.2, 4.61]
1 study · 234 participants
Very low

Low molecular weight heparin vs vitamin K antagonist (VKA)

Thrombocytopenia (up to 3 months)n · people with cancer with thrombosis prophylaxis and central venous catheters

Low‐molecular‐weight heparin (LMWH) probably leads to higher thrombocytopenia (up to 3 months)n compared with vitamin K antagonist (VKA) (moderate certainty).

1 finding from 1 review

Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes only
RR 1.69 [1.2, 2.39]
2 studies · 327 participants
Moderate

Low molecular weight heparin vs no LMWH

Symptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters

Low‐molecular‐weight heparin (LMWH) probably leads to lower symptomatic catheter‐related thrombosis (up to 3 months) compared with no LMWH (moderate certainty).

1 finding from 1 review

Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes only
RR 0.43 [0.22, 0.81]
5 studies · 1089 participants
Moderate

Low molecular weight heparin vs no LMWH

Symptomatic catheter‐related thrombosis measured as asymptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters

It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes symptomatic catheter‐related thrombosis measured as asymptomatic… compared with no LMWH (very low certainty).

1 finding from 1 review

Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes only
RR 0.95 [0.62, 1.46]
5 studies · 1089 participants
Very low

Low molecular weight heparin vs no LMWH

Major bleeding · people with cancer with thrombosis prophylaxis and central venous catheters

It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes major bleeding (up to 3 months) compared with no LMWH (very low certainty).

1 finding from 1 review

Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes only
RR 1.49 [0.06, 36.28]
4 studies · 1018 participants
Very low

Low molecular weight heparin vs no LMWH

Minor bleeding · people with cancer with thrombosis prophylaxis and central venous catheters

Low‐molecular‐weight heparin (LMWH) showed no clear difference in minor bleeding (up to 3 months) compared with no LMWH (low certainty).

1 finding from 1 review

Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes only
RR 1.35 [0.62, 2.92]
2 studies · 544 participants
Low

Low molecular weight heparin vs no LMWH

Antibiotic versus heparin only lock/flush solution: catheter‐related infections · people with cancer with thrombosis prophylaxis and central venous catheters

Low‐molecular‐weight heparin (LMWH) showed no clear difference in catheter‐related infection (up to 3 months) compared with no LMWH (low certainty).

1 finding from 1 review

Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes only
RR 0.97 [0.52, 1.79]
2 studies · 474 participants
Low

Low molecular weight heparin vs no LMWH

Thrombocytopenia · people with cancer with thrombosis prophylaxis and central venous catheters

Low‐molecular‐weight heparin (LMWH) showed no clear difference in thrombocytopenia (up to 3 months) compared with no LMWH (low certainty).

1 finding from 1 review

Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes only
RR 1.03 [0.8, 1.33]
4 studies · 1002 participants
Low

Comparison 7: Structured GP follow‐up vs TAU or another comparator

Repetition of SH at post‐intervention · self‐harm in adults

Comparison 7: Structured GP follow‐up showed no clear difference in repetition of SH at post‐intervention (hospital records) compared with TAU or another comparator (low certainty).

2 findings from 1 review

Psychosocial interventions for self‐harm in adults 2021 · Cochrane Headline outcomes only
OR 1.01 [0.38, 2.68]
1 study · 143 participants
Low
Psychosocial interventions for self‐harm in adults 2021 · Cochrane Headline outcomes only
OR 2.56 [0.8, 8.15]
1 study · 123 participants
Low

Psychoeducational follow‐up programme vs treatment

Reduction in physical signs End of treatment · people with conversion disorder according to DSM‐IV or ICD‐10 criteria

The review found no eligible studies for this question.

1 finding from 1 review

Psychosocial interventions for conversion and dissociative disorders in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Psychoeducational follow‐up programme vs treatment

Quality of life · people with conversion disorder according to DSM‐IV or ICD‐10 criteria

The review found no eligible studies for this question.

1 finding from 1 review

Psychosocial interventions for conversion and dissociative disorders in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found